Study design: The study is a two arm randomised controlled trial (randomisation ratio 1:1) comparing an aerobic exercise training intervention to usual care plus exercise advice. The primary outcome is the feasibility of the intervention as novel primary therapy in men with localised prostate cancer.

Inclusion Criteria:

In accordance with NICE active surveillance guidelines, men:

• Who have been evaluated using a combination of clinical, bio-chemical, imaging and/or biopsy, within the last 12 months
• With histologically confirmed low or intermediate risk prostate cancer, Gleason score ≤7 (3+4, not 4+3)
• With up to T2a clinical stage tumours
• With pre-treatment PSA ≤20 ng/mL
• Who are willing to participate in optimal active surveillance and provide written informed consent
• With life expectancy of ≥10 years

Exclusion Criteria:

Men:

• With unstable angina
• With uncontrolled hypertension
• With recent myocardial infarction (within the past 6 months)
• With pacemakers
• Already undertaking regular physical activity (greater than 90 minutes of moderate intensity exercise, per week) will be excluded
• With any other physical or mental limitation preventing participation in trial assessments
• Participating in other clinical trials which might bias the evaluation of the primary objectives of the present study